Press release

Last day of trading in warrants series TO 3 in Immunovia

Today, 11 April 2025, is the last day of trading in warrants series TO 3 in Immunovia AB (publ) ("Immunovia" or the "Company"). Subscription of shares by exercise of warrants series TO 3 is ongoing until 15 April 2025. One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.24 per share.

Immunovia carried out a rights issue of units during August – September 2024 (the “Rights Issue”). Each unit issued in the Rights Issue consisted of two (2) shares, two (2) warrants series TO 2 and one (1) warrant series TO 3. One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company. Today, 11 April 2025, is the last day of trading in warrants series TO 3.

Complete terms and conditions for the warrants are available on the Company's website, www.immunovia.com.

Summarized terms for warrants series TO 3:

Structure: One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company.
Exercise period: 1 April 2025 – 15 April 2025.
Subscription price: SEK 0.24 per share.
Issue volume: 62,211,989 warrants series TO 3. Upon full exercise, 62,211,989 shares will be issued and the Company will receive approximately SEK 14.9 million before issue costs.
Last day of trading in warrants of series TO 3: 11 April 2025.
Share capital and dilution: Upon full exercise of all 62,211,989 warrants series TO 3, the share capital will increase by a maximum of SEK 1,866,359.67 to SEK 9,723,625.56 through the issuance of a maximum of 62,211,989 new shares, resulting in that the total number of outstanding shares in the Company will increase from 261,908,863 to 324,120,852. Upon full exercise of all warrants series TO 3, the dilution amounts to approximately 19.2 percent.
Outcome and delivery of new ordinary shares: The outcome of the exercise of warrants will be published via a press release on or around 17 April 2025. Shares that have been subscribed and paid for may be registered on the subscriber’s securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Immunovia.

Please note that the warrants series TO 3 that are not exercised by 15 April 2025, or sold by 11 April 2025, will expire without value. In order for the warrants not to lose their value, active subscription of shares or sale of warrants is required. Please note that some nominees may close their application earlier than 15 April 2025.

Advisers
Vator Securities AB acts as financial adviser to Immunovia in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Immunovia in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.

IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Immunovia. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Immunovia has only been made through the prospectus published by Immunovia on 12 August 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company’s website, www.immunovia.com.

Since Immunovia is deemed to carry out protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act, the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products. The Company will, no later than in connection with the commencement of the exercise period for the warrants, publish more information about this on the Company’s website, www.immunovia.com.